Evaluation of Serum Proinflammatory Cytokine IL-17A and Tight Junction Protein Claudin-1 in Psoriasis

Table 1

Inclusion criteria and populations’ characteristics of the published studies conducted to evaluate the levels of IL-17A in the serum of psoriatic patients.

Study populations’ characteristics/inclusion criteria
Ref. number	Age (years)	Sex (F/M)	Psoriasis forms	Nail psoriasis	Psoriatic arthritis	Comorbidities	PASI (0–72)	IL-17A (pg/ml)	Treatment
[13]	Mean ± SD: 47.5 ± 7.6; Range: 25.0–72.0	41/81	Psoriasis vulgaris: 102/122	N/A	Present in 8/122	N/A	Mean ± SD:7.3 ± 4.2; Range: 0.7–32.3	Mean ± SD: 8.3 ± 3.8; Range:0.0–13.9	Treated, untreated, well-controlled, and poorly controlled cases. Treatments: topical steroid, topical vitamin D3, psoralen ultraviolet A, and systemic treatments (etretinate, ciclosporin)
			Guttate psoriasis: 7/122
			Erythrodermic psoriasis: 5/122
[12]	N/A	N/A	Moderate-severe plaque psoriasis	N/A	Excluded	N/A	N/A	N/A	Untreated topically or systematically ≥1 month before enrolment
[14]	N/A	20/14	Plaque psoriasis	N/A	N/A	N/A	N/A	Median: 6.9; Range: 5.3–8.8	N/A
[16]	Mean ± SD: 43.9 ± 15.2; Range: 18.0–71.0	21/27	Plaque psoriasis	N/A	N/A	N/A	N/A	Mean ± SD: 10.5 ± 60.4	Untreated topically (apart from emollients) and systematically ≥4 weeks before enrolment
[21]	Mean ± SD: 35.0 ± 15.5; Range: 7.0–79.0	12/18	Plaque psoriasis	N/A	N/A	N/A	Mean ± SD: 9.3 ± 8.2; Range: 1.5–33.3	Mean ± SD: 8.3 ± 3.8; Range: 0.0–13.9	Untreated topically or systematically ≥2 months before enrolment
[15]	Mean ± SD: 39.9 ± 14.9	34/36	Plaque psoriasis: 30	N/A	N/A	N/A	Mean ± SD: 6.6 ± 5.4	Mean ± SD: 6.6 ± 8.0	Newly diagnosed or without systemic treatment ≥2 months before enrolment
			Guttate psoriasis: 20
			Pustular psoriasis: 20
[22]	Mean ± SD: 45.6 ± 13.2 Range: 18.0–69.0	10/50	Psoriatic patients	N/A	N/A	N/A	Mean ± SD: 15.7 ± 9.7; Range: 4.8–64.2	Mean ± SD: 3.2 ± 1.8	N/A
[23]	Mean ± SD: 44.5 ± 15.6; Range: 23.0–72.0	23/9	Active, chronic plaque psoriasis	Excluded	Excluded	N/A	Mean ± SD: 5.2 ± 3.7; Range: 2.2–15.0	Mean ± SD: 2.7 ± 3.5; Range: 0.0–8.6	Untreated topically and systematically ≥1 year before enrolment
[24]	Mean ± SD: 43.7 ± 12.4; Range: 20.0–60.0	30/22	Plaque psoriasis	Present in 12/52	Excluded	N/A	Mean ± SD:4.6 ± 1.9; Range: 2.1–9.0	Mean ± SD: 4.3 ± 6.2; Range: 0.0–28.5	Untreated topically or systematically ≥1 year before enrolment
[25]	Mean ± SD: 44.8 ± 15.2		Plaque psoriasis	N/A	N/A	N/A	N/A	Range: 38.8–9.0	N/A
[17]	Mean ± SD: 50.2 ± 13.3	24/30	Plaque psoriasis	N/A	N/A	N/A	Median: 16.4; Range: 7.0–41	Median: 3.9; Range: 3.9–3530	N/A
[26]	Mean ± SD: 36.6 ± 14.2	N/A	Plaque psoriasis: 38	N/A	N/A	N/A	Mean ± SD: 8.2 ± 4.0	Mean ± SD: 1.4 ± 2.4	Untreated topically or systematically ≥4 weeks before enrolment
			Guttate psoriasis: 30
[27]	Mean: 51.8 Range: 50.0–70.0	20/0	Pustular palmoplantar psoriasis	N/A	N/A	N/A	N/A	Mean ± SD: 2.0 ± 4.13; Range: 0.0–17.1	Untreated topically ≥2 weeks and systematically ≥4 months before enrolment
[28]	Mean ± SD: 29.7 ± 13.5	7/27	Plaque psoriasis	N/A	N/A	N/A	Mean ± SD: 4.9 ± 3.0; Range: 0.5–11.4	N/A	Untreated topically ≥2 weeks and systematically ≥8 weeks before enrolment
[18]	Mean: 37.0; Range: 16.0–65.0	13/17	Plaque psoriasis	N/A	N/A	N/A	Mean ± SD: 20.5 ± 8.5	Mean ± SD: 2.5 ± 1.7	Untreated topically ≥6 weeks and systematically ≥3 months before enrolment
[19]	Median: 38.8	0/8	Plaque psoriasis	N/A	N/A	N/A	N/A	Median: 0.5	N/A
[20]	N/A	2/3	N/A	N/A	N/A	N/A	N/A	Mean ± SD: 0.7 ± 0.1	N/A
[29]	>18	24/36	Severe psoriasis	N/A	Present in 26/70	Present in 30/60	N/A	Mean ± SD: 2.6 ± 3.2; Range: 1.8–3.4	N/A
[30]	Mean: 42.1 ± 15.0	12/28	Severe plaque psoriasis	N/A	N/A	N/A	Mean ± SD: 9.8 ± 6.3	N/A	N/A
Our study	Mean ± SD: 31.8 ± 16.2; Range: 10–73	14/29	Plaque psoriasis	Present in 32/43	Present in 8/43	Present in 32/43	Mean ± SD: 3.6 ± 3.0; Range: 0.2–15.2	Mean ± SD: 20.9 ± 0.3; Range: 17.1–25.2	Treated, untreated, well-controlled, and poorly controlled cases. Treatments: topical steroid, topical vitamin D3, psoralen ultraviolet A, and systemic treatments (etretinate, ciclosporin)

Ref. no.: reference number; F/M: females/males; N/A: not available; ^∗data retrieved from the abstract, since no full-text file was available. N/A, not available.